Opinion of the Transparency Council – pomalidomide
At its meeting on 25 November 2024, the Transparency Council adopted opinion No. 183/2024 on the inclusion in the reimbursement of medicines containing the active substance pomalidomide as regards indications for use or dosage or route of administration different from those specified in the summary of product characteristics, i.e. plasmocytic myeloma (ICD-10: C90.0)